Evaluations were conducted on cell viability, apoptosis ratio, and oxidative stress indicators (MDA, SOD, and ROS ... The cells were lysed for 30 min on ice in RIPA buffer (20-188, Merck, Tarmstadt, ...

Taking a further step towards obtaining a BMD (Ballistic Missile Defense) capability against hypersonic missiles, the MDA (Missile Defense Agency) and the U.S. Navy fired a simulated Standard ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Google Maps is the most popular app with more than a billion active users monthly. It uses various icons and symbols to represent various places. Every symbol and icon used on Google Maps and what ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Mer­ck has struck a li­cens­ing deal for a car­dio­vas­cu­lar drug with Jiang­su Hen­grui Phar­ma­ceu­ti­cals, the lat­est in a flood of Chi­na deals be­ing made by … ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. Merck has entered an exclusive licensing ...

Merck was one of the pioneers of the cholesterol-lowering statins that launched in the 1980s and 1990s and changed medical practice. But it hasn’t been as successful with cholesterol medicines since ...